ENDRA Life Sciences (NDRA) Accounts Payables (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Accounts Payables for 11 consecutive years, with $647934.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 44.49% year-over-year to $647934.0 in Q2 2026; TTM through Jun 2026 was $647934.0, a 44.49% increase from a year earlier, with the FY2025 full-year figure at $621578.0, up 22.29% from the prior year.
• Accounts Payables was $647934.0 for Q2 2026 at ENDRA Life Sciences, down from $701487.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $2.0 million in Q3 2023 and troughed at $439688.0 in Q1 2025.
• A 5-year average of $1.0 million and a median of $869976.0 in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 77.8% in 2022 and plunged 68.23% in 2024, its largest moves.
• Over 5 years, Accounts Payables stood at $1.5 million in 2022, then sank by 53.99% to $700754.0 in 2023, then dropped by 27.46% to $508293.0 in 2024, then grew by 22.29% to $621578.0 in 2025, then increased by 4.24% to $647934.0 in 2026.
• The last three Accounts Payables figures came in at $647934.0 (Q2 2026), $701487.0 (Q1 2026), and $621578.0 (Q4 2025), per Business Quant data.